199 related articles for article (PubMed ID: 26490362)
1. Drug Permeation Characterization of Inhaled Dry Powder Formulations in Air-Liquid Interfaced Cell Layer Using an Improved, Simple Apparatus for Dispersion.
Asai A; Okuda T; Sonoda E; Yamauchi T; Kato S; Okamoto H
Pharm Res; 2016 Feb; 33(2):487-97. PubMed ID: 26490362
[TBL] [Abstract][Full Text] [Related]
2. Safety Evaluation of Dry Powder Formulations by Direct Dispersion onto Air-Liquid Interface Cultured Cell Layer.
Asai A; Okuda T; Yamauchi T; Sugiura Y; Okamoto H
Biol Pharm Bull; 2016; 39(3):368-77. PubMed ID: 26754254
[TBL] [Abstract][Full Text] [Related]
3. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
4. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
5. Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer.
Vartiainen V; Bimbo LM; Hirvonen J; Kauppinen EI; Raula J
Pharm Res; 2017 Jan; 34(1):25-35. PubMed ID: 27604893
[TBL] [Abstract][Full Text] [Related]
6. Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate.
Kumar V; Sethi B; Yanez E; Leung DH; Ghanwatkar YY; Cheong J; Tso J; Narang AS; Nagapudi K; Mahato RI
Int J Pharm; 2022 Mar; 615():121470. PubMed ID: 35041913
[TBL] [Abstract][Full Text] [Related]
7. Novel dry powder inhalation system based on dispersion of lyophilisates.
Claus S; Schoenbrodt T; Weiler C; Friess W
Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
[TBL] [Abstract][Full Text] [Related]
8. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
[TBL] [Abstract][Full Text] [Related]
9. In vitro investigation on the impact of airway mucus on drug dissolution and absorption at the air-epithelium interface in the lungs.
Cingolani E; Alqahtani S; Sadler RC; Prime D; Stolnik S; Bosquillon C
Eur J Pharm Biopharm; 2019 Aug; 141():210-220. PubMed ID: 31154066
[TBL] [Abstract][Full Text] [Related]
10. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
Shalash AO; Molokhia AM; Elsayed MM
Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
12. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
Akdag Cayli Y; Sahin S; Buttini F; Balducci AG; Montanari S; Vural I; Oner L
Drug Dev Ind Pharm; 2017 Aug; 43(8):1378-1389. PubMed ID: 28420285
[TBL] [Abstract][Full Text] [Related]
13. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
Hein S; Bur M; Schaefer UF; Lehr CM
Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
[TBL] [Abstract][Full Text] [Related]
14. Development of a dry powder insufflation device with application in in vitro cell-based assays in the context of respiratory delivery.
Pontes JF; Diogo HP; Conceição E; Almeida MP; Borges Dos Santos RM; Grenha A
Eur J Pharm Sci; 2024 Jun; 197():106775. PubMed ID: 38643941
[TBL] [Abstract][Full Text] [Related]
15. Delivery of Dry Powders to the Lungs: Influence of Particle Attributes from a Biological and Technological Point of View.
Zellnitz S; Roblegg E; Pinto J; Fröhlich E
Curr Drug Deliv; 2019; 16(3):180-194. PubMed ID: 30360739
[TBL] [Abstract][Full Text] [Related]
16. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of the DP-4M PennCentury insufflator.
Hoppentocht M; Hoste C; Hagedoorn P; Frijlink HW; de Boer AH
Eur J Pharm Biopharm; 2014 Sep; 88(1):153-9. PubMed ID: 24993307
[TBL] [Abstract][Full Text] [Related]
18. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
Bur M; Huwer H; Muys L; Lehr CM
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary dispersion formulations: the impact of dispersed powder properties on pressurized metered dose inhaler stability.
O'Donnell KP; Williams RO
Drug Dev Ind Pharm; 2013 Mar; 39(3):413-24. PubMed ID: 23216244
[TBL] [Abstract][Full Text] [Related]
20. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
Cordts E; Steckel H
Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
